Clinical trials: Cirrhosis Liver
Hepatocellular Carcinoma
Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis
The purpose of this study is to evaluate 3 imaging techniques and their associations : MRI, CTscanner and enhanced contrast ultrasound for the diagnosis of small (< 3 cm) hepatocellular carcinoma for patients with cirrhosis.
- Trial name
- CHIC (NCT00848952)
- Testing
- 3 imaging techniques are done
- Where
- 19 sites in France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Angers
Proton Pump Inhibitor Adverse Reaction, Liver Cirrhosis
Proton Pump Inhibitors in Cirrhotic Patients
Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients.
- Trial name
- NCT06384443
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- National Liver Institute, Egypt
Liver Cirrhosis
Role of Blood Lactate Level in Prediction of Outcome of Cirrhotic Patients at The Intensive Care Unit
1. Determine in-hospital and 28-days mortality rates of critically-ill cirrhotic patients admitted to ICU 2. Evaluate the role of (blood lactate level, lactate/albumin ratio, lactate/bilirubin index and MELD-lactate score) in…
- Trial name
- NCT06121908
- Volunteers
- 50 people
- Sponsor
- Assiut University
Cirrhosis
TIPS With Coated Stents for Refractory Ascites in Patients With Cirrhosis
The main end point of the study is to assess survival in cirrhotic patients with refractory ascites treated by TIPS (using PTFE covered stents) vs patients treated by paracentesis + albumin infusion.
- Trial name
- NCT00222014
- Testing
- TIPS, Paracenthese
- Where
- 4 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Toulouse
Hepatic Encephalopathy
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE)…
- Trial name
- RED-C-3132 (NCT05297448)
- Testing
- Rifaximin SSD
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 517 people
- Sponsor
- Bausch Health Americas, Inc.
Cirrhosis, Liver
To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis
The study is a single-center, single-arm, open-label, dose-escalation clinical study, to evaluate the tolerability, safety and preliminary efficacy of CUD005 injection in patients with cirrhosis
- Trial name
- NCT06296095
- Testing
- Cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Primary Bilary Cirrhosis (PBC)
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
- Trial name
- SENSE registry (NCT07549607)
- Where
- 21 sites in Germany, Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Leipzig
Liver Cirrhosis
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
- Trial name
- NCT00592475
- Testing
- conivaptan
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cumberland Pharmaceuticals
Esophageal and Gastric Varices, Liver Cirrhosis
Prevention of Esophageal Varices by Beta-Adrenergic Blockers
The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease.
- Conditions
- Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
- Trial name
- NCT00006398
- Testing
- Timolol Maleate
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 213 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B, Cirrhosis
Prevention of Recurrent Hepatitis B After Liver Transplantation
Hepatitis B accounts for approximately 5000 deaths per year in the United States. Liver transplantation offers the only hope for patients who develop end-stage liver disease.
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT00059267
- Testing
- HBIG, Epivir, Hepsera
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cirrhosis
Microvesicles and Monocytes to Predict Mortality of Patients with Cirrhosis
Chronic liver diseases related to viral hepatitis, metabolic syndrome or excessive alcohol consumption can evolve towards cirrhosis. Cirrhosis is responsible for 170 000 deaths per year in Europe.
- Trial name
- PROMICE (NCT03837444)
- Where
- 5 sites in France
- Volunteers
- 335 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nonalcoholic Steatohepatitis
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
This is a randomized, controlled trial to determine whether Losartan is effective at slowing down, halting or reversing liver fibrosis in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- FELINE (NCT01051219)
- Testing
- Losartan
- Where
- 10 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Portal Vein Thrombosis
Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV
Portal vein thrombosis (PVT) in patients with liver cirrhosis may be due to neoplastic growth or non-neoplastic causes. Treating PVT with anticoagulation in liver cirrhosis is difficult to be established but may be of great…
- Trial name
- NCT03201367
- Testing
- Rivaroxaban, symptomatic therapy for ascites, abdominal pain
- Volunteers
- 40 people
- Sponsor
- Zagazig University
Liver Cirrhosis
Sleep Disorders Pre and Post Liver Transplantation
Sleep disturbance and sexual dysfunction are common complaints of patients with cirrhosis . The term sleep disturbance describes insomnia, poor quality sleep, circadian rhythm disorders and obstructive sleep apnea and is…
- Trial name
- NCT01002001
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Liver Diseases, Fibrosis, Liver
Liver Cancer Prevention Randomized Control Trial
To determine the effectiveness of a behaviorally-based tailored disease management intervention in patients with fibrosis or steatosis and risk factors for cirrhosis.
- Conditions
- Liver Diseases, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05196867
- Testing
- Intervention Group, Control Group
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis, Hepatitis B, Chronic
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Conditions
- Hepatitis, Hepatitis B, Chronic, Cirrhosis
- Trial name
- NCT00076336
- Testing
- Telbivudine, Lamivudine
- Where
- 28 sites in United States, Australia and 19 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Alcohol-Related Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease.
- Trial name
- NCT07450144
- Testing
- LLM-based chatbot, Telephone counseling, Alcohol Brief Intervention
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
The purpose of the study is to evaluate the efficacy and safety of a treatment regimen of 12 weeks or 8 weeks of simeprevir in combination with sofosbuvir in chronic hepatitis C virus (HCV) genotype 1 infected men and women…
- Trial name
- NCT02114177
- Testing
- Simeprevir, Sofosbuvir
- Where
- 40 sites in United States, Canada
- Volunteers
- 310 people
- Sponsor
- Janssen Infectious Diseases BVBA
NASH - Nonalcoholic Steatohepatitis, Liver Fibroses
Liquid Biopsy for NASH and Liver Fibrosis
Nonalcoholic fatty liver disease (NAFLD) has evolved to represent the most common cause of chronic liver disease globally. Today, NAFLD is a leading indication for liver transplantation and a major etiology for hepatocellular…
- Trial name
- LIBRA (NCT04677101)
- Testing
- Liver Biopsy
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
Cirrhosis, Compensated Cirrhosis
The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis
This pilot study to determine the feasibility of EUS-Portal Pressure Measurements to guide Beta-Blocker Therapy in patients with compensated cirrhosis .The study will be a prospective tandem controlled trial consisting of 30…
- Conditions
- Cirrhosis, Compensated Cirrhosis, Portal Hypertension
- Trial name
- NCT05357599
- Testing
- EUS
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.